Skip to main content
. Author manuscript; available in PMC: 2019 Aug 6.
Published in final edited form as: J Pediatr. 2018 Jul 18;201:40–48.e4. doi: 10.1016/j.jpeds.2018.05.021

Table VI.

Cognitive impairment*

LCA-based cognitive impairment level (n = 812)
Severe n = 64 Moderate n = 135 Low Normal n = 333 Normal n = 280
Elevated inflammatory proteins
IRG1 Ref Ref Ref Ref
 IRG2 3.79 (1.72–8.36) 3.93 (2.08–7.41) 2.54 (1.48–4.34) Ref
 IRG3 2.18 (0.61–7.78) 3.18 (1.29–7.83) 1.53 (0.69–3.38) Ref
Elevated neurotrophic proteins
 NRG1 Ref Ref Ref Ref
 NRG2 0.31 (0.12–0.79) 0.46 (0.24–0.88) 0.62 (0.39–0.98) Ref
 NRG3 0.85 (0.37–1.95) 1.03 (0.55–1.95) 1.00 (0.60–1.67) Ref

IRG2 defined by elevation of CRP or SAA with other proteins having little or modest elevations.

IRG3 defined by ≥3 other protein elevations without CRP and SAA elevations.

NRG2 defined by elevation of 2 of RANTES, BDNF, or ANG-1 with other proteins having little or modest elevations.

NRG3 defined by ≥3 other proteins elevated protein elevations without CRP and SAA elevations.

Values are adjusted OR (95% CI).

Bold values represent ORs for which the 95% confidence limits do not include 1; ie, significantly different from 1 at P < .05.

*

At 10 years of age for those with sustained elevated inflammatory and neurotrophic proteins (controlling for infant sex and maternal education).